Alembic Pharma shares rally 12% on USFDA nod for cancer drug
Shares of
Alembic Pharmaceuticals
climbed as much as 12% on Monday to Rs 1,089.80 on BSE after the company received final approval from the US Food and Drug Administration (USFDA) for its generic version of
Doxorubicin Hydrochloride Liposome Injection
, a
cancer treatment
drug.
In a press release issued Sunday, the company announced that it had received final
USFDA approval
for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
New Container Houses Indonesia (Prices May Surprise You)
Container House | Search ads
Search Now
Undo
The company noted,
'The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), of Baxter Healthcare Corporation.'
The injection is indicated for the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.
'Refer to label for detailed indication,'
the company said.
Citing IQVIA data, Alembic estimated the market size of Doxorubicin Hydrochloride Liposome Injection in the U.S. to be $29 million for the twelve months ending March 2025.
Live Events
Growing US pipeline
Alembic's cumulative count of USFDA approvals now stands at 224 ANDAs, comprising 201 final approvals and 23 tentative approvals.
Earlier this month, on June 18, the company also received an Establishment Inspection Report (EIR) from the USFDA for its API-III facility in Karakhadi, following an inspection conducted from March 17 to March 21, 2025.
Stock performance and technicals
Alembic's stock has been on a steady uptrend. It has gained 22.7% in the past year, 2.5% in the past six months, 15.7% over the last three months, and 6.8% in the past month.
From a technical standpoint, the stock is currently trading above all its key simple moving averages (5-day to 200-day), signaling bullish momentum across time frames. The Relative Strength Index (RSI) is at 52.4, indicating neutral territory, while the Moving Average Convergence Divergence (MACD) is at 2.4, staying above its center line though still below its signal line.
The stock hit a 52-week high of Rs 1,296.15 on October 9, 2024, and a 52-week low of Rs 725.60 on March 3, 2025.
Also read |
Godrej Properties shares in focus after Rs 600 crore Panipat land deal
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
34 minutes ago
- Time of India
Delhi developer to invest $2 billion on India data centre boom
Anant Raj Ltd. plans to spend Rs 180 billion ($2.1 billion) on data centres as it joins a growing list of Indian companies looking to ride the boom in demand for artificial intelligence and business process-led services in the country. The Delhi-based developer with a market value of $2.3 billion will launch two more data centres or server farms in the northern Indian state of Haryana. This is in addition to the one already operational, as it aims for a capacity of little over 300 megawatts by 2032, Amit Sarin, managing director at Anant Raj said. For context, India's data centre capacity is poised to grow by 77% to 1.8 gigawatts in the next four years, according to a 2025 report by property consultant JLL. 'India is witnessing one of the fastest growth phases globally for data centres,' said Sarin in an interview, adding that the project will be funded through the company's own funds. Anant Raj's move follows ambitious plans by India's top business houses Adani Group and Reliance Industries Ltd. to expand their footprint. The trend is underscored by Barclays Plc's view that the South Asian nation will be a big beneficiary of the data centre investment boom in Asia, driven by digitalization and rules requiring data to be stored within the country. Smaller firms are not far behind. Bengaluru-based RMZ Corp. is spending $1.7 billion on two data centres and Panchshil Realty is considering partnering with Blackstone Inc. to build a large data centre in Mumbai. Data centres are expected to make up more than 40% of Anant Raj's revenues in the next four years from 5% at present, Sarin said. The company tied up with the French IT company Orange Business to provide cloud services to its clients along with data centres last year. 'India currently generates 28% of the world's data but houses only 1% of it locally, presenting a significant opportunity for expansion as data localization becomes inevitable,' Sarin said.
Time of India
36 minutes ago
- Time of India
Sigachi temporarily suspends production at Hyderabad unit for 90 days after fire incident
Sigachi Industries on Monday said production at its Hyderabad plant , which saw a fire incident leading to the death of several workers, would be paused for around 90 days to restore affected equipment and structures. In addition to the human impact, the incident also caused damage to certain ancillary equipment and civil structures within the facility, it said in a regulatory filing. At least 12 people died and 34 persons were injured in an explosion at Sigachi Industries' plant in this district on Monday, Telangana Minister Damodara Raja Narasimha said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like New Barefoot Shoe Has Seniors Walking Off the Weight Barefoot Vitality Undo The pharmaceutical company in an exchange filing said, "... on June 30, 2025, at approximately 9:20 AM (IST), a fire incident occurred in the vicinity of our Hyderabad Plant located at Pashamylaram, Phase -1, Medak District." "The incident has unfortunately resulted in loss of human life, and there may have been individuals who sustained injuries. While the exact number of injuries is currently being confirmed, the well-being of our personnel remains our foremost priority." Live Events A thorough on-ground assessment of the situation is currently in progress, and the company is coordinating with relevant authorities to ensure all safety and support protocols are followed, it added. "While the core manufacturing infrastructure has suffered damage, the operations at the plant will be temporarily paused for an estimated period of 90 days to facilitate replacement and restoration of affected equipment and structures," the company said. The company operates three manufacturing facilities for Microcrystalline Cellulose (MCC), one of which is the Hyderabad unit where the incident occurred. The unit contributes around 6,000 MTPA out of the total operating capacity of 21,700 MTPA, with the balance production coming from our other two facilities located in Gujarat, it added. The other two plants continue to operate normally, and efforts are being made to optimise production from those units during the interim period, the company said. "The Hyderabad facility is fully insured, and we are in the process of initiating the necessary claims as per standard procedures. We remain committed to resuming operations at the earliest, with enhanced focus on safety, risk mitigation, and operational excellence," it said. Shares of the pharma company, which is one of the major Microcrystalline Cellulose manufacturers globally, ended 11.58 per cent down at Rs 48.79 apiece on BSE.
Business Standard
42 minutes ago
- Business Standard
Torrent Pharma gains after inking pact to acquire majority stake in JB Chemicals & Pharma
Torrent Pharmaceuticals added 2.22% to Rs 3,418.60 after the company entered into definitive agreement with KKR to acquire controlling stake in JB Chemicals and Pharmaceuticals at an equity valuation of Rs 25,689 crore. Shares of JB Chemicals & Pharmceuticals declined 6.63% to Rs 1,680.05 on the BSE. The acquisition would provide access to a fast growing India franchise, with leading brands in the chronic segment, and entry into untapped therapeutic areas like ophthalmology. It strengthens market share in the IPM for Torrent and offers operational synergies across multiple business functions. The deal also supports platform diversification through entry into the CDMO segment with long-term potential. Additionally, it facilitates consolidation in key international markets and greater ability to scale up. The transaction will be executed in two phases. In first phase, the company will acquire 7,44,81,519 equity shares, representing a 46.39% stake at Rs 1,600 per share, for a total consideration of Rs 11,917 crore from the promoter seller, KKR. Additionally, the company plans to acquire up to 44,99,782 shares, representing a 2.80% stake at the same price of Rs 1,600 per share, from certain employees of JB Chemicals & Pharmaceuticals. Furthermore, the company will launch an open offer to acquire 4,17,45,264 equity shares or 26% stake at Rs 1,639.18 per share from public shareholders of JB Chemicals & Pharmaceuticals. In second phase, the company will merge with JB Pharma through a scheme of arrangement. As per the approved by the board of directors of both companies, shareholders of JB Pharma will receive 51 shares of Torrent for every 100 shares held in JB Pharma upon completion of the merger. Samir Mehta executive chairman, Torrent, commented: We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrents deep India presence and JB Pharmas fast growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market, and build a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent. Gaurav Trehan, co-head of Asia Pacific and head of Asia Pacific Private Equity, KKR, and CEO of KKR India, said: JB Pharmas transformation under our stewardship is a testament to KKRs ability to scale high-quality companies. We are proud to have collaborated with JB Pharmas management team, led by Nikhil Chopra, to bring the breadth of KKRs global experience and operational expertise to support the companys organic and inorganic growth, and help JB Pharma become one of Indias fastest growing branded pharmaceutical companies. We believe the company is well-positioned for continued growth ahead and wish the team every success in its next chapter with Torrent. Torrent Pharma is the flagship company of the Torrent Group. It is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It has 8 manufacturing facilities, of which 5 are USFDA approved. J.B. Chemicals & Pharmaceuticals is a public listed company primarily engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations.
